Myocardial Fibrosis in Hypertensive Heart Failure Does Quality Rather Than Quantity Matter?∗ by Moon, James C. et al.
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 7 , N O . 3 , 2 0 1 6
ª 2 0 1 6 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O UN DA T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 5 . 1 0 . 0 7 0EDITORIAL COMMENTMyocardial Fibrosis in
Hypertensive Heart Failure
Does Quality Rather Than Quantity Matter?*James C. Moon, MD,yz Thomas A. Treibel, MBBS,yz Erik B. Schelbert, MD, MSx“It is quality rather than quantity that matters.”
—Lucius Annaeus Seneca (1)SEE PAGE 251T he biology of heart failure is complex anddiverse (2), posing challenges for developingefﬁcacious therapies. All but one recent phase
III heart failure trial failed to reduce mortality (3). Un-
like oncology, we do not split heart failure into sub-
types on the basis of disease pathways (4). We need a
more targeted approach, not only for drug develop-
ment, but also for drug response monitoring. Myocar-
dial ﬁbrosis is an attractive biomarker—ﬁbrosis is
already an established marker in the liver, kidneys,
and lung—and likely a causal disease pathway medi-
ating outcomes. Cardiac ﬁbrosis can be measured on
myocardial biopsy and tracks disease severity and
outcome (5,6). But biopsy is invasive and impractical
for routine clinical diagnosis and monitoring (7).
Many of our current measurements are partial surro-
gates for ﬁbrosis (e.g., imaging for cardiac remodeling,
systolic and diastolic function), but more are needed,
particularly circulating blood biomarkers. Cardiology
quantiﬁes only 2 myocardial processes routinely using*Editorials published in the Journal of the American College of Cardiology
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and nonspeciﬁc strain (B-type natriuretic peptides).
Imagine the clinical impact if dozens more were avail-
able, speciﬁc for different activated myocardial
disease pathways. Circulating collagen turnover bio-
markers are attractive candidates. However, the heart
is just one intermediate-sized organ releasing markers
of (non–organ-speciﬁc) collagen pathways into the
bloodstream. To date, collagen turnover does not suf-
ﬁciently pass the litmus test of correlating with the
gold standard of cardiac histology, tracking interven-
tion, or adding value for diagnosis, prognosis, and
therapeutic monitoring (8,9). New approaches are
needed. Fibrosis pathways are complex, and lurking
within may be more cardiac-speciﬁc processes.In this issue of the Journal, López et al. (10)
investigated patients with a subset of heart failure,
hypertensive heart failure. Rather than analyzing
standard biomarkers of collagen quantity, they
focused on collagen quality, speciﬁcally, collagen
cross-linking (CCL), which has been shown to in-
crease myocardial stiffness. The ratio of soluble and
insoluble collagen by histology reﬂects CCL (11).
First, the authors invasively measured on biopsy
CCL in health and in 38 hypertensive heart failure
patients, who they dichotomized into normal and
high CLL groups. Interestingly, the 2 groups did not
differ in total collagen or collagen I volume fractions.
But the collagen quality (via CCL) correlated well at
baseline with left ventricular ejection fraction, dia-
stolic function, and N-terminal pro–B-type natriuretic
peptide, and with risk of hospitalization for heart
failure (HHF) over 7 years.
Secondly, they developed biomarkers of CCL.
Collagen I degradation occurs via cleavage by matrix
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262metalloproteinase (MMP)-1, which generates the
degradation product C-terminal telopeptide of
collagen type I (CITP). However, when extensive
cross-linking occurs, CITP production is lower. The
ratio of MMP-1 to CITP is, therefore, a potential
biomarker of cardiac CCL. They showed that the
CITP:MMP-1 ratio inversely correlated with CCL;
receiver-operating characteristic analysis showed
reasonable sensitivity (82%) and speciﬁcity (70%),
and identiﬁed a cutoff point for predicting high
myocardial CCL (#1.968).
Thirdly, in a new cohort of hypertensive HF pa-
tients (n ¼ 203, 4.5-year follow-up), the CITP:MMP-1
ratio was measured and the cohort dichotomized
into low ratio (high CCL) and normal (normal CCL).
A low CITP:MMP-1 ratio was associated with higher
rates of hospitalization (54% vs. 34%), increased
risk of HHF on multivariate analysis (adjusted haz-
ard ratio: 2.22), and improved risk prediction of
HHF. There was no difference in cardiovascular
mortality.
How does this story differ from other candidate
biomarker stories? First, it tracked qualitative as well
as quantitative changes. Secondly, it surpassed other
candidates (e.g., osteopontin) as a histological
ﬁbrosis measure and appeared to add value beyond
the raw collagen volume fraction (12). Thirdly, it
predicted outcome. The downsides of the story are
limited generalizability, as it focuses on hypertensive
HF—although a homogeneous HF subset avoids the
pitfalls of mixing the various HF etiologies in an
attempt to increase sample size.
Other questions remain. Collagen metabolism is
not organ-speciﬁc (13,14). Even if linked to outcome,
the source of the CITP:MMP-1 is not deﬁnitively the
heart—these pathways are, for example, active in thearterial wall, causing arterial stiffness (and peripheral
blood correlated better to CCL than the coronary si-
nus samples) (15). Using a ratio of 2 biomarkers feels
suspect—with X biomarkers, X factorial combinations
are possible—ﬁnding positive statistical associations
by chance becomes easier (multiple comparisons),
even if combinations are constrained to plausible
biological pathways. Outcome-linked confounders
(noncardiac ﬁbrotic disease, renal dysfunction) also
may generate noncausative associations.
The heart shares many disease pathways observed
in other organs. Current proteomics can detect 4,000
myocardial proteins active in hundreds of pathways
(16). The high concentration of proteins and obvious
pathways may not yield peripheral cardiac-speciﬁc
biomarkers. New myocardium-speciﬁc imaging bio-
markers, such as the extracellular volume fraction by
cardiovascular magnetic resonance, quantify the
whole spectrum of myocardial ﬁbrosis noninvasively,
and early data show it predicts outcome robustly (17);
combining this with markers of collagen quality is an
attractive avenue. Nevertheless, the authors deserve
praise for their innovative approach to translate
myocardial ﬁbrosis into the clinical arena. Their
remarkable efforts—multidecadal basic science, dis-
covery in tissue, passing tests by correlation with
organ-speciﬁc imaging surrogates, translation to
circulating biomarkers, and validation in large
external cohorts—all informed by clinical need—
advances our knowledge signiﬁcantly.
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